Camille L. Bedrosian - Jun 18, 2025 Form 4 Insider Report for RHYTHM PHARMACEUTICALS, INC. (RYTM)

Role
Director
Signature
/s/ Stephen Vander Stoep, attorney-in-fact for Camille L. Bedrosian
Stock symbol
RYTM
Transactions as of
Jun 18, 2025
Transactions value $
$0
Form type
4
Date filed
6/23/2025, 04:52 PM
Previous filing
Jun 13, 2025
Next filing
Jun 26, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Bedrosian Camille L Director 222 BERKELEY STREET, 12TH FLOOR, BOSTON /s/ Stephen Vander Stoep, attorney-in-fact for Camille L. Bedrosian 2025-06-23 0001326969

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RYTM Common Stock Options Exercise +4K +133.33% 7K Jun 18, 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RYTM Restricted Stock Units Options Exercise $0 -4K -100% $0.00 0 Jun 18, 2025 Common Stock 4K Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
F2 The restricted stock units fully vested on June 18, 2025. The restricted stock units have no expiration date.